Market Newsdesk

NEW YORK, Jan. 18, 2026 (GLOBE NEWSWIRE) — Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.

If you invested in Integer, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/integer-holdings-corporation-class-action-lawsuit.

Investors have until February 9, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Integer common stock. The case is pending in the U.S. District Court for the Southern District of New York and is captioned West Palm Beach Firefighters’ Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251.

Why is Integer Being Sued For Securities Fraud?

Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology (“EP”) devices that map the heart’s electrical activity to diagnose and treat arrhythmias.

During the relevant period, Integer repeatedly touted its EP sales growth and market position while overstating demand for its EP devices.

As alleged, in truth, demand for and revenue from Integer’s EP products had fallen sharply—directly contradicting the Company’s public assurances.

Why did Ineger’s Stock Drop?

On October 23, 2025, Integer disclosed that it lowered its 2025 sales guidance to a range between $1.840 billion and $1.854 billion, from a range between $1.850 billion and $1.876 billion, and well below analysts’ estimates. The Company also revealed that it expected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. Integer also admitted that two of its EP devices experienced “slower than forecasted” adoption and that it expected the slower demand “to continue into 2026.” This news caused the price of Integer stock to drop $35.22 per share, or more than 32%, from a closing price of $109.11 per share on October 22, 2025, to $73.89 per share on October 23, 2025.

Click here for more information:

https://www.bfalaw.com/cases/integer-holdings-corporation-class-action-lawsuit

.

What Can You Do?

If you invested in Integer, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/integer-holdings-corporation-class-action-lawsuit

Or contact:
Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/integer-holdings-corporation-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Jan. 18, 2026 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Fermi Inc. (NASDAQ: FRMI), certain of the Company’s senior executives and directors, and underwriters of Fermi’s Initial Public Offering after a significant stock drop resulting from potential violations of the federal securities laws.

If you invested in Fermi, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/fermi-inc-class-action-lawsuit.

Investors have until March 6, 2026, to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Fermi securities, as well as claims under Sections 11 and 15 of the Securities Act of 1933 on behalf of investors who purchased or acquired Fermi common stock pursuant and traceable to the Company’s Initial Public Offering. The case is pending in the U.S. District Court for the Southern District of New York and is captioned Lupia v. Fermi Inc., et al., No. 1:26-cv-00050.

Why is Fermi Being Sued for Violations of the Federal Securities Laws?

Fermi is an energy and AI infrastructure company that purportedly intends to build multiple, large scale nuclear reactors to support its own network of large, grid-independent data centers powered by nuclear and other energy to power AI companies. Fermi’s first project is Project Matador, its flagship, first-of-its kind energy and AI infrastructure campus designed to provide dedicated power for AI workloads.

Fermi completed its IPO in October 2025. In the IPO Registration Statement, Fermi represented that it “entered into a letter of intent . . . with an investment grade-rated tenant (the ‘First Tenant’) to lease a portion of the Project Matador Site . . . for an initial lease term of twenty years.” The Company also represented there was strong demand for Project Matador and that construction of the facility would be funded by “tenant payments” and “lease agreements.” Following the IPO, Fermi announced that the First Tenant entered into an Advance in Aid of Construction Agreement, through which it would advance up to $150 million to Fermi to fund Project Matador construction costs.

As alleged, in truth, Fermi overstated tenant demand for Project Matador and misrepresented the agreement with the First Tenant.

Why did Fermi’s Stock Drop?

On December 12, 2025, Fermi disclosed that “[o]n December 11, 2025, the First Tenant notified the Company that it is terminating the [Advance of Aid of Construction Agreement]” after “[t]he exclusivity period set forward in the letter of intent expired.” Fermi also stated that it had “commenced discussions with several other potential tenants” and “continue[s] to negotiate the terms of a lease agreement at Project Matador” with the First Tenant. This news caused the price of Fermi stock to drop $5.16 per share, or more than 33%, from a closing price of $15.25 per share on December 11, 2025, to $10.09 per share on December 12, 2025.

Click here for more information:

https://www.bfalaw.com/cases/fermi-inc-class-action-lawsuit

.

What Can You Do?

If you invested in Fermi, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/fermi-inc-class-action-lawsuit

Or contact:
Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/fermi-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Jan. 18, 2026 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Bath & Body Works, Inc. (NYSE:BBWI) and certain of the Company’s senior executives for securities fraud after significant stock drops resulting from the potential violations of the federal securities laws.

If you invested in Bath & Body Works, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/bath-body-works-inc-class-action-lawsuit.

Investors have until March 16, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Bath & Body Works securities. The case is pending in the U.S. District Court for the Southern District of Ohio and is captioned Lingam v. Bath & Body Works, Inc., et al., No. 2:26-cv-00039.

Why is Bath & Body Works Being Sued for Securities Fraud?

Bath & Body Works is a specialty retailer of home fragrance and body care products. During the relevant period, the Company explored product categories, or “adjacencies,” beyond its core business. The key adjacencies included products for men, lips, hair, and laundry.

Bath & Body Works stated that customers were “responding favorably to innovation” including “adjacencies” of men’s, lip, and laundry. The Company also stated that its “strategy is working,” and that the Company was driving topline growth through “extending our reach through category adjacencies.”

As alleged, in truth, Bath & Body Works’ strategy of pursuing adjacencies was not growing the customer base or delivering the promised level of growth in net sales.

Why did Bath & Body Works’ Stock Drop?

On August 28, 2025, Bath & Body Works reported disappointing Q2 2025 financial results and announced it was cutting its full year guidance for earnings per diluted share by $0.03, to $3.28 to $3.53. This news caused the price of Bath & Body Works stock to drop $2.18 per share, or 6.9%, from a closing price of $31.54 per share on August 27, 2025, to $29.36 per share on August 28, 2025.

Then, on November 20, 2025, Bath & Body Works released its Q3 2025 financial results. The Company announced it was slashing full year guidance and revealed that its strategy of pursuing “adjacencies, collaborations and promotions” had “not grown our total customer base.” The Company also revealed it would exit certain adjacencies to focus on core categories. This news caused the price of Bath & Body Works stock to drop $5.22 per share, or 24.8%, from a closing price of $21.04 per share on November 19, 2025, to $15.82 per share on November 20, 2025.

Click here for more information:


https://www.bfalaw.com/cases/bath-body-works-inc-class-action-lawsuit


.

What Can You Do?

If you invested in Bath & Body Works, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/bath-body-works-inc-class-action-lawsuit

Or contact:
Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/bath-body-works-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Jan. 18, 2026 (GLOBE NEWSWIRE) — Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. (NYSE:ARE) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.

If you invested in Alexandria Real Estate, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/alexandria-real-estate-class-action-lawsuit.

Investors have until January 26, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Alexandria Real Estate securities. The case is pending in the U.S. District Court for the Central District of California and is captioned Hern v. Alexandria Real Estate Equities, Inc., et al., No. 2:25-cv- 11319.

Why is Alexandria Real Estate Being Sued For Securities Fraud?

Alexandria Real Estate is a real estate investment trust. Its tenants are concentrated in life science industries, such as pharmaceutical and biotechnology companies.

During the relevant period, Alexandria Real Estate touted its leasing volume and development pipeline, specifically regarding a property in Long Island City, New York, stating that leasing volume was “solid” and its pipeline was “well positioned to capture future demand when expansion needs arise.”

As alleged, in truth, Alexandria Real Estate was experiencing lower occupancy rates and slower leasing activity such that it was required to take a real estate impairment charge of $323.9 million with $206 million attributed to its Long Island City property.

Why did Alexandria Real Estate’s Stock Drop?

On October 27, 2025, Alexandria Real Estate announced results below expectations for 3Q 2025 and cut guidance for the remainder of the fiscal year. The company attributed the results to lower occupancy rates and slower leasing activity. It also announced a real estate impairment charge of $323.9 million with $206 million attributed to its Long Island City property, stating that the property was not a life science destination that could scale. Alexandria Real Estate also announced additional impairment charges that may be recognized in 4Q 25 ranging from $0 to $685 million. This news caused the price of Alexandria Real Estate stock to drop $14.93 per share, or more than 19%, from a closing price of $77.87 per share on October 27, 2025, to $62.94 per share on October 28, 2025.

Click here for more information:

https://www.bfalaw.com/cases/alexandria-real-estate-class-action-lawsuit

.

What Can You Do?

If you invested in Alexandria Real Estate you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/alexandria-real-estate-class-action-lawsuit

Or contact:
Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/alexandria-real-estate-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Jan. 18, 2026 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that it has filed a class action lawsuit against Ardent Health, Inc. (NYSE:ARDT) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from potential violations of the federal securities laws.

If you invested in Ardent Health, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ardent-health-inc-class-action-lawsuit.

Investors have until March 9, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Ardent Health securities. The class action is pending in the U.S. District Court for the Middle District of Tennessee. It is captioned Postiwala v. Ardent Health, Inc., et al., No. 3:26-cv-00022.

Why is Ardent Health Being Sued for Securities Fraud?

Ardent Health and its affiliates operate acute care hospitals and other healthcare facilities. A critical aspect of Ardent Health’s operations is the collection of accounts receivable and the framework by which Ardent Health determines the collectability of such accounts. According to the lawsuit, Ardent Health stated that it employed an active monitoring process to determine the collectability of its accounts receivable, and that this process included “detailed reviews of historical collections” as a “primary source of information.” 

As alleged, in truth, Ardent Health did not primarily rely on “detailed reviews of historical collections” in determining collectability of accounts receivable, but instead “utilized a 180-day cliff at which time an account became fully reserved.” This allowed Ardent Health to report higher amounts of accounts receivable during the Class Period, and delay recognizing losses on uncollectable accounts. The lawsuit alleges that Ardent Health’s purported misrepresentations are a violation of the federal securities laws.

Why did Ardent Health’s Stock Drop?

On November 12, 2025, after market hours, Ardent Health revealed it had completed “hindsight evaluations of historical collection trends” that resulted in a $43 million decrease in revenue for the quarter. Ardent Health also revealed that it increased its professional liability reserves by $54 million because of “adverse prior period claim developments” resulting from a set of claims between 2019 and 2022 “as well as consideration of broader industry trends.”

This news caused the price of Ardent Health stock to drop $4.75 per share, or more than 33%, from a closing price of $14.05 per share on November 12, 2025, to $9.30 per share on November 13, 2025.

Click here for more information:

https://www.bfalaw.com/cases/ardent-health-inc-class-action-lawsuit

.

What Can You Do?

If you invested in Ardent Health, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/ardent-health-inc-class-action-lawsuit

Or contact:
Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/ardent-health-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Jan. 18, 2026 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against CoreWeave, Inc. (NASDAQ:CRWV) and certain of the Company’s senior executives for securities fraud after significant stock drops resulting from the potential violations of the federal securities laws.

If you invested in CoreWeave, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/coreweave-inc-class-action-lawsuit.

Investors have until March 13, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in CoreWeave securities. The case is pending in the U.S. District Court for the District of New Jersey and is captioned Masaitis v. CoreWeave, Inc., et al., No. 2:26-cv-00355.

Why is CoreWeave Being Sued For Securities Fraud?

CoreWeave is an AI-focused cloud computing company that builds and operates data centers offering high-performance GPU infrastructure. CoreWeave relies on multiple partners to develop its data centers and provide the infrastructure needed for its AI computing operations, including Core Scientific, a large digital infrastructure company. On July 7, 2025, CoreWeave announced a merger agreement with Core Scientific.   

During the relevant period, CoreWeave repeatedly assured investors it could capitalize on the “robust” and “unprecedented” demand for its services given its “competitive strengths,” including its ability to “deploy” AI infrastructure “at massive scale” and “rapidly scale our operations.”

As alleged, in truth, CoreWeave overstated its ability to meet customer demand and concealed significant construction delays at its data centers.

Why did CoreWeave’s Stock Drop?

On October 30, 2025, Core Scientific announced it did not receive enough shareholder votes to approve the merger with CoreWeave and, as a result, terminated the merger agreement. This news caused the price of CoreWeave stock to drop $8.87 per share, or more than 6%, from $139.93 per share on October 29, 2025, to $131.06 per share on October 30, 2025.

Then, on November 10, 2025, CoreWeave lowered guidance for revenue, operating income, capital spending, and active power capacity for 2025 due to “temporary delays related to a third-party data center developer who is behind schedule.” This news caused the price of CoreWeave stock to drop $17.22 per share, or more than 16%, from $105.61 per share on November 10, 2025, to $88.39 per share on November 11, 2025.

Finally, on December 15, 2025, The Wall Street Journal reported that the “completion date” for a “huge data-center cluster” in Denton, Texas to be leased by OpenAI, “has been pushed back several months,” and that the site builder, Core Scientific, had flagged delays at the site months earlier. The Wall Street Journal also reported that Core Scientific had flagged additional delays at sites in Texas and elsewhere “since at least February.” This news caused the price of CoreWeave stock to drop $2.85 per share, or more than 3%, from $72.35 per share on December 15, 2025, to $69.50 per share on December 16, 2025.

Click here for more information:

https://www.bfalaw.com/cases/coreweave-inc-class-action-lawsuit

.

What Can You Do?

If you invested in CoreWeave, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/coreweave-inc-class-action-lawsuit

Or contact:
Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/coreweave-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

• Canada slashes 100% tariffs on Chinese EVs to 6.1%, directly benefiting Lotus Technology Inc. (NASDAQ: LOT)—the only mobility provider with Chinese-made EV entering the North American market above the $80,000 price segment.
• Under the new policy, the planned retail price of the Eletre in Canada is expected to be revised down approximately 50%, with wholesale deliveries projected to achieve exponential growth.
• Leveraging its North American homologation completed in 2024 and well-established retail network of authorized dealers in Canada, Lotus Tech is well-positioned to capitalize on this market opportunity.

NEW YORK, Jan. 17, 2026 (GLOBE NEWSWIRE) — Lotus Technology Inc. (“Lotus Tech” or the “Company”) (Nasdaq: LOT), a leading global intelligent and luxury mobility provider has expressed significant attention and a warm welcome to the new tariff policy announced by the Canadian government. Prime Minister Mark Carney announced that Canada will allow an initial annual cap of 49,000 Chinese electric vehicles (“EV”) into the Canadian market under a preferential tariff rate of 6.1%. This landmark policy adjustment not only signifies positive progress in China-Canada trade relations but also strongly propels the further development of Lotus Tech in the North American market.

It opens a compelling opportunity for strategic repositioning for Lotus Tech. As the brand’s first all-electric hyper SUV, Eletre, with its outstanding product capabilities, successfully completed rigorous North American market homologation in 2024. It stands as the only Chinese-made EV currently entering the North American market in the price segment above US$80,000. This favorable tariff policy is expected to directly reshape the Eletre’s pricing strategy in the Canadian market with approximately 50% reduction to its planned retail price. Combined with Lotus’ “For the Drivers” philosophy of delivering an ultimate driving experience, a more competitive pricing strategy is anticipated to drive exponential growth in its sales volume in Canada.

The Company’s global strategic layout with 210 regional stores covering 61 countries has laid a solid foundation for seizing this opportunity. Lotus Tech has a well-established retail network across Canada with 6 authorized dealerships, offering a full range of services from classic internal combustion engine models to the latest electric products. Thanks to its pre-established market access homologation and channel development, Lotus Tech is well-positioned to swiftly translate the policy benefits into market share.

Mr. Qingfeng Feng, Chief Executive Officer of Lotus Tech, commented: “Canada has always been a strategically vital market within Lotus’ global footprint, where auto consumers possess a high appreciation for performance and driving pleasure. We extend our warm welcome to the new, optimized tariff policy, which creates a more open and fair market environment for international auto brands. Building upon our prior groundwork in the North American market, we will seize this opportunity to enhance investment in Canada to explore any potential tactical advantages and strengthen our footprint in the North American market. We are committed to pursuing growth in a disciplined manner that aligns with market development and creates sustainable value.”

About Lotus Technology Inc.

Lotus Technology Inc. has operations across the UK, the EU and China. The Company is dedicated to delivering luxury lifestyle electric vehicles, with a focus on world-class R&D in next-generation automobility technologies such as electrification, digitalisation and more. For more information about Lotus Technology Inc., please visit www.group-lotus.com. 

Forward-Looking Statements

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential”, “forecast”, “plan”, “seek”, “future”, “propose” or “continue”, or the negatives of these terms or variations of them or similar terminology although not all forward-looking statements contain such terminology. Forward-looking statements involve inherent risks and uncertainties, including those identified under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and Lotus Technology Inc. undertakes no obligation to update any forward-looking statement, except as required under applicable law.

Contact Information

For investor inquiries
[email protected]